BTK and lymphoma: A BTK‐targeting spirooxindole PROTAC was able to induce > 85% degradation of BTK in 6 h in RAMOS lymphoma cells and had efficacy against the C481S mutant form of BTK, a key resistance variant to ibrutinib (IC50 = 0.13 μM in RAMOS cells) (Rampeesa et al. 2024).